Dr. David Defeo, M.D.
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Hahneman Medical College of the Pacific (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 602
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Hahneman Medical College of the Pacific
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
NC license 200401199 -
Pulmonary Disease Physician
NC license 200401199 -
Sleep Medicine (Internal Medicine) Physician
NC license 200401199
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health Forsyth Medical Center Winston-Salem, NC
- Novant Health Thomasville Medical Center Thomasville, NC
Medical groups
- Novant Health Medical Group, LLC (2,430 clinicians)
- Spectrum Medical Group PA (15 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 602
- Services billed
- 2,921
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test to measure expiratory airflow and volume | 355 | 348 |
| Established patient office or other outpatient visit, 30-39 minutes | 218 | 201 |
| Test to examine how well the lungs exchange gases | 207 | 204 |
| Established patient office or other outpatient visit, 40-54 minutes | 172 | 142 |
| X-ray of chest, 2 views | 110 | 101 |
| Critical care, first 30-74 minutes | 82 | 47 |
| New patient office or other outpatient visit, 60-74 minutes | 72 | 72 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 67 | 63 |
| Test for exercise-induced lung stress | 61 | 59 |
| Evaluation of use of breathing device | 57 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Winston Salem, NC | 275 |
| Montelukast Sodium Other prescribers in Winston Salem, NC | 260 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Winston Salem, NC | 248 |
| Prednisone Other prescribers in Winston Salem, NC | 236 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Winston Salem, NC | 118 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Winston Salem, NC | 99 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Winston Salem, NC | 88 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Winston Salem, NC | 78 |
| Doxycycline Hyclate Other prescribers in Winston Salem, NC | 57 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Winston Salem, NC | 53 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 64 payments worth $1,404 in total to this clinician.
| Inspire Medical Systems, Inc. | $204 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $195 |
| Grifols USA, LLC | $128 |
| GlaxoSmithKline, LLC. | $105 |
| United Therapeutics Corporation | $86.28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $83.65 |
| Viatris Specialty LLC | $79.22 |
| Regeneron Healthcare Solutions, Inc. | $78.64 |
| Food and Beverage | $1,386 |
|---|---|
| Education | $17.38 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Insmed, Inc. Sep 17, 2025 | Education Brinsupri; Brinsupri · Respiratory · in-kind | $17.38 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $128,421 in research payments for these studies, mostly to the institutions running them.
- A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibro…
Boehringer Ingelheim Pharmaceuticals, Inc. - Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi US Services Inc. · Recruiting · NCT07190209 - Real-world effectiveness of mepolizumab in treating chronic obstructiv
GlaxoSmithKline, LLC. - A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with id…
Boehringer Ingelheim Pharmaceuticals, Inc. - A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibro…
Boehringer Ingelheim International GmbH - A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with id…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.